|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE3414831A1
(de)
|
1984-04-19 |
1985-10-31 |
Hoechst Ag, 6230 Frankfurt |
Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
|
|
DE3536939A1
(de)
|
1985-10-17 |
1987-04-23 |
Hoechst Ag |
Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
DE4036856C1
(https=)
|
1990-11-19 |
1992-05-27 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De |
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5770191A
(en)
|
1995-05-24 |
1998-06-23 |
University Of Florida |
Active C-terminal peptides of interferon--gamma and their use
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
EP1002861A1
(en)
|
1998-10-26 |
2000-05-24 |
Unilever Plc |
Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
|
|
US20020142000A1
(en)
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
|
CA2477192A1
(en)
|
2000-05-18 |
2001-11-18 |
Japan Tobacco, Inc. |
Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
|
|
WO2002059264A2
(en)
|
2000-12-29 |
2002-08-01 |
Bio-Technology General Corp. |
Specific human antibodies for selective cancer therapy
|
|
FR2822845B1
(fr)
|
2001-03-30 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
|
|
FR2823763A1
(fr)
|
2001-04-18 |
2002-10-25 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'interferon alpha 6
|
|
FR2823764B1
(fr)
|
2001-04-24 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
|
|
FR2824333B1
(fr)
|
2001-05-03 |
2003-08-08 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
|
|
FR2825102B1
(fr)
|
2001-05-23 |
2003-08-29 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
|
|
FR2825716B1
(fr)
|
2001-06-11 |
2004-09-24 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
|
|
US7647184B2
(en)
|
2001-08-27 |
2010-01-12 |
Hanall Pharmaceuticals, Co. Ltd |
High throughput directed evolution by rational mutagenesis
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
EP1539950A1
(en)
|
2002-09-09 |
2005-06-15 |
Nautilus Biotech |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
JP3803790B2
(ja)
|
2003-02-17 |
2006-08-02 |
株式会社東北テクノアーチ |
新規なダイアボディ型二重特異性抗体
|
|
CA2441653A1
(en)
|
2003-09-19 |
2005-03-19 |
William Herman |
Targeted ligands
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
DE602004030811D1
(de)
|
2003-10-16 |
2011-02-10 |
Micromet Ag |
Multispezifische deimmunisierte cd3-bindende moleküle
|
|
PT1678314E
(pt)
|
2003-10-22 |
2012-11-27 |
Keck Graduate Inst |
Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
|
KR100891620B1
(ko)
|
2004-04-13 |
2009-04-02 |
에프. 호프만-라 로슈 아게 |
항-ｐ-셀렉틴 항체
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
US20060024272A1
(en)
|
2004-07-29 |
2006-02-02 |
Large Scale Biology Corporation |
C-terminally truncated interferon
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
|
DK2650020T3
(en)
|
2005-05-06 |
2017-01-16 |
Providence Health & Services - Oregon |
Trimeric OX40 immunoglobulin fusion protein and methods for applications.
|
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
|
AR057807A1
(es)
|
2005-09-12 |
2007-12-19 |
Novimmune Sa |
Formulaciones de anticuerpo anti-cd3
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
WO2009030679A1
(en)
|
2007-09-03 |
2009-03-12 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Method for prolonging longevity
|
|
CN101925612A
(zh)
|
2007-11-27 |
2010-12-22 |
维文蒂阿生物技术公司 |
针对癌相关的nfkbib变体的表位的抗体及其用途
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
CA2738568C
(en)
|
2008-10-01 |
2024-02-20 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
JP6126782B2
(ja)
|
2008-10-01 |
2017-05-10 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
JP5861223B2
(ja)
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
CN102946906B
(zh)
|
2010-04-23 |
2015-07-15 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
SMT201700185T1
(it)
|
2010-08-23 |
2017-05-08 |
Univ Texas |
Anticorpi anti-ox40 e metodi di uso degli stessi
|
|
MX340556B
(es)
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
MX2014003313A
(es)
*
|
2011-09-23 |
2014-07-09 |
Amgen Res Munich Gmbh |
Moleculas de union biespecificas para 5t4 y cd3.
|
|
US20130165638A1
(en)
*
|
2011-12-27 |
2013-06-27 |
Development Center For Biotechnology |
Light chain-bridged bispecific antibody
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
WO2014012085A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
US20140072581A1
(en)
|
2012-07-23 |
2014-03-13 |
Zymeworks Inc. |
Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
|
|
CA2886036A1
(en)
|
2012-09-25 |
2014-04-03 |
Ichnos Sciences SA |
Purification of hetero-dimeric immunoglobulins
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
EP2914634B1
(en)
|
2012-11-02 |
2017-12-06 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
|
EP3766903A3
(en)
|
2012-11-13 |
2021-02-17 |
BioNTech SE |
Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
|
|
EP3878964A1
(en)
|
2012-11-27 |
2021-09-15 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
US9703815B2
(en)
|
2012-12-17 |
2017-07-11 |
Salesforce.Com, Inc. |
Third party files in an on-demand database service
|
|
EP2935589A1
(en)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CA2902739C
(en)
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
WO2015095412A1
(en)
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
CN106459173A
(zh)
|
2014-05-02 |
2017-02-22 |
爱默蕾大学 |
人源化可变淋巴细胞受体（vlr）及其相关组合物和用途
|
|
US20170103186A1
(en)
|
2014-06-03 |
2017-04-13 |
Amgen Inc. |
Systems and methods for supporting patient use of a drug delivery device
|
|
GB201411420D0
(en)
|
2014-06-26 |
2014-08-13 |
Ucb Biopharma Sprl |
Antibody constructs
|
|
CA2952532A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
ES2777305T5
(en)
*
|
2014-09-04 |
2025-09-30 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
AU2015323313B2
(en)
|
2014-09-25 |
2021-04-01 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
EP3204416A1
(en)
*
|
2014-10-09 |
2017-08-16 |
EngMab AG |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
CN110894240B
(zh)
*
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
ES2935274T3
(es)
|
2014-12-05 |
2023-03-03 |
Merck Patent Gmbh |
Anticuerpo con intercambio de dominios
|
|
US10941207B2
(en)
*
|
2014-12-19 |
2021-03-09 |
Chiome Bioscience, Inc |
Fusion protein comprising three binding domains to 5T4 and CD3
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
CA2968141C
(en)
|
2015-01-16 |
2020-08-04 |
Hsing-Mao CHU |
Molecular constructs with targeting and effector elements
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
JP7001474B2
(ja)
|
2015-01-21 |
2022-01-19 |
インヒブルクス，インコーポレイティド |
非免疫原性単一ドメイン抗体
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
KR102734408B1
(ko)
|
2015-05-04 |
2024-11-27 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137에 특이적인 신규한 단백질
|
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
CA3155409A1
(en)
|
2015-05-13 |
2016-11-17 |
Ablynx N.V. |
T cell recruiting polypeptides based on cd3 reactivity
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
AU2016297249B2
(en)
|
2015-07-23 |
2020-11-12 |
Inhibrx Biosciences, Inc. |
Multivalent and multispecific GITR-binding fusion proteins
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
LT3353212T
(lt)
|
2015-09-23 |
2021-12-27 |
Regeneron Pharmaceuticals, Inc. |
Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
|
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
|
WO2017060144A1
(en)
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
|
WO2017123673A2
(en)
|
2016-01-11 |
2017-07-20 |
Inhibrx Lp |
Multivalent and multispecific ox40-binding fusion proteins
|
|
KR20180096789A
(ko)
|
2016-01-11 |
2018-08-29 |
인히브릭스, 인크. |
다가 및 다중특이적 41bb-결합 융합 단백질
|
|
GB201602156D0
(en)
|
2016-02-05 |
2016-03-23 |
Jones Philip C And Boku University Of Natural Resources And Life Sciences |
Heterodimers and purification thereof
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
JP7038353B2
(ja)
|
2016-04-13 |
2022-03-18 |
ヴィヴィア バイオテック，エス．エル |
エクスビボのｂｉｔｅ活性化ｔ細胞
|
|
AU2017252233A1
(en)
*
|
2016-04-22 |
2018-11-15 |
Alligator Bioscience Ab |
Novel bispecific polypeptides against CD137
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
WO2018027025A1
(en)
|
2016-08-03 |
2018-02-08 |
Oncomed Pharmaceuticals, Inc. |
Cd40-binding agents and uses thereof
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
CN108084265B
(zh)
*
|
2016-11-23 |
2021-07-02 |
复旦大学 |
特异性结合人的5t4抗原的全人源单域抗体及其应用
|
|
BR112019013189A2
(pt)
|
2017-01-03 |
2019-12-10 |
Hoffmann La Roche |
moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
|
|
CA3056542A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
|
AU2018247796A1
(en)
|
2017-04-04 |
2019-08-29 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
|
|
AU2018250641B2
(en)
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
RU2020124623A
(ru)
|
2017-12-27 |
2022-01-27 |
Тенеобио, Инк. |
Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|